

0590  
1621  
CM1 10/10

0420  
08/02/01

CASE LA 24B CNT1

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

Ronald S. Herman  
Type or print name

Ronald S. Herman  
Signature

9/17/01  
Date

RECEIVED  
NOV 30 2001  
TECHNICAL CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

ROBL ET AL.

Examiner: Not Assigned Yet

APPLICATION NO: 09/905,235

FILED: JULY 13, 2001

FOR: METHOD FOR TREATING ATHEROSCLEROSIS EMPLOYING AN  
AP2 INHIBITOR AND COMBINATION

Assistant Commissioner for Patents  
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed within three months of the filing date of the application. Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-3880.


In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449. A copy of the reference is enclosed herewith.

Applicant also submits copies of PTO-1449 and PTO-1449 Supplemental relating to parent application U.S. Serial No. 09/390,275 filed September 7, 1999. Copies of these references can be found in the parent application, or can be provided by the undersigned attorney upon request.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000  
(609) 252-5781

  
\_\_\_\_\_  
Ronald S. Hermenau  
Attorney for Applicants  
Reg. No. 34,620


Date: 9/17/01

**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

ATTY. DOCKET NO.  
LA 24B CNT1  
APPLICATION NO.  
09/905,235  
APPLICANT  
ROBL ET AL.  
FILING DATE  
JULY 13, 2001

Group



**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM	WO/96/35678	11/14/96	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AN						<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>


**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	
	AS	
	AT	

**EXAMINER**

**DATE CONSIDERED**

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.



FORM PTO-1449

**INFORMATION DISCLOSURE STATEMENT**

Docket No.: LA24b

Serial No.: 09/390,275

Applicant: Jeffrey A. Robl et al

Filing Date: 09/07/99

Sheet 1 of 1

TECHNICAL GROUP 1614

RECEIVED  
NOV 30 2001  
TECHNICAL GROUP 1600/2900

**U.S. PATENT DOCUMENTS**

Examiner Initial		Document Number	Date	Name	Class	Sub-class	Filing Date
	AA	4,001,228	01/04/77	Mattalia			
	AB	4,051,250	09/27/77	Dahm et al			
	AC	5,187,188	02/16/93	Meanwell			
	AD	5,218,124	06/08/93	Failli et al			
	AE	5,262,540	11/16/93	Meanwell			
	AF	5,348,969	09/20/94	Romine et al			
	AG	5,362,879	11/08/94	Meanwell			
	AH	5,380,854	01/10/95	Romine et al			
	AI	5,403,852	04/04/95	Barreau et al			
	AJ	5,599,770	02/04/97	Kubota et al			
	AK						

**FOREIGN PATENT DOCUMENTS**

Examiner Initial		Document Number	Date	Country	Class	Sub-class	Filing Date
	AL	2.1.56.486	01/06/73	France (English Abstract attached)			
	AM	2.647.676	07/12/90	France (English Abstract attached)			
	AN	WO92/04334	19/03/92	PCT			
	AO	WO95/17393	29/06/95	PCT			
	AP						

**OTHER (Including Author, Title, Date, Pertinent Pages, etc.)**

	AQ	Hotamisligil, G.S. et al, "Uncoupling of Obesity from Insulin Resistance Through a Targeted Mutation in aP2, the Adipocyte Fatty Acid Binding Protein", Science, Vo. 274, Nov. 22, 1996, pp 1377-1379.
	AR	Mai, A. et al, "Dihydro(alkylthio)(naphthylmethyl)oxopyrimidines: Novel Non-Nucleoside Reverse Transcriptase Inhibitors of the S-DABO Series", J. Med. Chem., 1997, 40, 1447-1454
	AS	Dialog Alert DBDR928, Jan. 2, 1997, Pharmaprojects No. 5149
	AT	
	AU	
	AV	
	AW	
	AX	
	AY	
	AZ	

FORM PTO-1449  
(REV. 7-96)

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

**INFORMATION DISCLOSURE CITATION**

ATTY. DOCKET NO.  
LA 2411  
APPLICATION NO.  
09/300,278  
APPLICANT  
KOH, ET AL  
FILING DATE  
SEPTEMBER 7, 1999

Sheet 1 of 1


Supp.

NOV 3 0 2001

Group  
1014

TECH CENTER 1600/2900

RECEIVED



**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM						<input type="checkbox"/>	<input type="checkbox"/>
	AN						<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	Baxa, et al. Biochemistry, Vol. 28, No. 22, 1989 pgs. 8683-8690.
	AS	
	AT	

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.